Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 187 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial February 20, 2020 FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF... March 11, 2026 Innovative cancer spinouts: 3 new projects get green light August 13, 2021 No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... November 17, 2025 Load more HOT NEWS Today is Random Acts of Kindness Day New study supports extending cervical screening intervals for people who test... Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... Telehealth-Based Cancer Care Surged during COVID. Will It Continue?
